Filter
Reset all

Subjects

Content Types

Countries

Data access

Data access restrictions

Database access

Data licenses

Data upload

Enhanced publication

Institution responsibility type

Institution type

Keywords

PID systems

Provider types

Quality management

Repository languages

Repository types

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 2 result(s)

Amsterdam Cohort Studies on HIV infection and AIDS

ACS

Subject(s)
Content type(s)
Country
<<<!!!<<< stated 26-02-2020: Amsterdam Cohort Studies on HIV infection and AIDS is no longer available online >>>!!!>>> The Amsterdam cohort study (ACS) on human immunodeficiency virus (HIV) infection and AIDS among homosexual men started in 1984 and was expanded to include drug users in 1985. Thus far, about 2100 homosexual men and 1630 (injecting) drug users have been included of whom approximately 700 homosexual men and 550 drug users are still in active follow-up. Every 3-6 months participants complete a standardized questionnaire to obtain medical, epidemiological and social scientific information and undergo a medical examination. In addition, they have blood drawn for virological and immunological tests and storage.

Liverpool COVID-19 Drug Interactions

Subject(s)
Content type(s)
Country
The COVID-19 pandemic has affected every country in the world. It is well documented that those most susceptible to the worst outcomes of COVID-19 are the immunocompromised and those with underlying comorbidities. Therefore, patients requiring treatment for COVID-19 will also be on additional medication, posing a risk for drug-drug interactions (DDIs). In order to address this, the Liverpool Drug Interactions website team developed this freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medications.